Effect of SAMe-TT<sub>2</sub>R<sub>2</sub> score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin

<p dir="ltr">There is no strong evidence on pharmacogenetics role on the quality of INR control after the initiation phase and on the maintenance of stable INR on the long term as measured by the time in therapeutic range (TTR). The benefit of a score such as SAMe-TT<sub>2</...

Full description

Saved in:
Bibliographic Details
Main Author: Hazem Elewa (3592601) (author)
Other Authors: Iqrah Qurishi (14151573) (author), Rawan Abouelhassan (14151576) (author), Salam Abou Safrah (14151579) (author), Eman Alhamoud (14151582) (author), Loulia Bader (14151585) (author)
Published: 2020
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<p dir="ltr">There is no strong evidence on pharmacogenetics role on the quality of INR control after the initiation phase and on the maintenance of stable INR on the long term as measured by the time in therapeutic range (TTR). The benefit of a score such as SAMe-TT<sub>2</sub>R<sub>2</sub> is that it can preemptively guide clinicians on whether to start the patient on warfarin or direct oral anticoagulant. To determine the association between genetic variants in <i>CYP2C9, VKORC1, </i>and <i>CYP4F2</i> and TTR. To validate SAMe-TT<sub>2</sub>R<sub>2</sub> score predictive ability on the quality of anticoagulation in Qatari patients. This is an observational nested case–control study that was conducted on a cohort of Qatari patients treated with warfarin with previously identified genotype for the <i>CYP2C9, VKORC1, </i>and<i> CYP2F4</i>. The sample size of this cohort was 148 patients. Mean TTR was 62.7 ± 21%. TTR was not significantly different among carriers of the <i>CYP2C9*2 &*3, VKORC1(–1639G>A) </i>or<i> CYP4F2*3 </i>compared to their non-carriers alleles. None of the factors in the SAMe-TT<sub>2</sub>R<sub>2</sub> score had a significant effect on the TTR except for the female gender where TTR was significantly lower in females (n = 89) compared to males (n = 59) (59.6 ± 21% vs. 67.2 ± 20%, p = 0.03). Furthermore, patients with SAMe-TT<sub>2</sub>R<sub>2</sub> score of zero had significantly better TTR compared to those with higher scores (76.5 ± 17% vs. 61.8 ± 21%, p = 0.04). Logistic regression analysis showed that high SAMe-TT<sub>2</sub>R<sub>2</sub> score was the only statistically significant predicting factor of poor INR control (odds ratio (OR) 5.7, 95% confidence interval (CI) 1.1–28.3, p = 0.034). Genetic variants have no contribution to the quality of INR control. SAMe-TT<sub>2</sub>R<sub>2</sub> score was predictive for the poor quality of anticoagulation in a cohort of Qatari patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Thrombosis and Thrombolysis<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s11239-020-02102-x" target="_blank">http://dx.doi.org/10.1007/s11239-020-02102-x</a></p>